CASP3 and metabolic dysfunction-associated steatotic liver disease: Analyzing cytokeratin 18 (marker indicating hepatocyte caspase-3 activation within the apoptosis pathway) fragments in serum demonstrates the capability to anticipate histologically confirmed NASH and assess the severity of the disease in a significant and diverse population of individuals with NAFLD [11,23].